Sensyne Health plc
("Sensyne" or the "Company")
Issue of New Ordinary Shares and Total Voting Rights
Oxford, U.K. - 18 March 2022: Sensyne Health plc (LSE:SENS) ("Sensyne" or the "Company") today announces that it has issued a total of 1,428,571 new ordinary shares of ten pence nominal value ("New Ordinary Shares").
These New Ordinary Shares have been issued to Great Ormond Street Hospital for Children (GOSH) under the terms of the previously announced strategic research agreements that Sensyne entered into with GOSH on 2 September 2021 and follow the completion of a valuation exercise as required under Section 593 of the Companies Act.
Application has been made to the London Stock Exchange for the admission of the 1,428,571 New Ordinary Shares to trading on AIM and it is expected that admission will become effective and that dealings will commence at 8.00 a.m. on or around 21 March 2022.
Total Voting Rights
Following the allotment of the New Ordinary Shares, the total number of ordinary shares following admission will be 166,227,710 with each ordinary share carrying the right to one vote. The Company has no shares in Treasury; therefore, following admission the total number of voting rights in Sensyne will be 166,227,710. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify an interest in, or change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
-ENDS-
Notes for editors:
About Sensyne Health: https://www.sensynehealth.com/
Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organisations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
Contact details:
| Sensyne Health | |
| |
| Lord (Paul) Drayson PhD FREng, Chief Executive Officer Dr Richard Pye, Chief Financial Officer | +44 (0) 330 058 1845 |
| |
| Peel Hunt LLP (Nominated Adviser and Joint Broker) | + 44 (0) 20 7418 8900 |
| |
| Dr Christopher Golden James Steel
| |
| |
| Liberum (Joint Broker) | | ||
| Phil Walker William Hall | + 44 (0) 20 3100 2000 | ||
| Consilium Strategic Communications | | ||
| Mary-Jane Elliott Jessica Hodgson CSCSensynehealth@consilium-comms.com | +44 (0) 7780 600290 | ||
| | | ||
| | | ||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
